Treatment patterns and annual biologic costs in US veterans with rheumatic conditions or psoriasis

References

• Myasoedova E, Crowson CS, Kremers HM, et al. Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 2010;62:1576-82
   PubMed Web of Science ®Google Scholar
• Meier FM, Frerix M, Hermann W, et al. Current immunotherapy in rheumatoid arthritis. Immunotherapy 2013;5:955-74
   PubMed Web of Science ®Google Scholar
• Helmick CG, Lee-Han H, Hirsch SC, et al. Prevalence of psoriasis among adults in the U.S.: 2003–2006 and 2009–2010 National Health and Nutrition Examination Surveys. Am J Prev Med 2014;47:37-45
   PubMed Web of Science ®Google Scholar
• Kircik LH, Del Rosso JQ. Anti-TNF agents for the treatment of psoriasis. J Drugs Dermatol 2009;8:546-59
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(2 Suppl):ii14-17
   PubMedGoogle Scholar
• Day MS, Nam D, Goodman S, et al. Psoriatic arthritis. J Am Acad Orthop Surg 2012;20:28-37
   PubMed Web of Science ®Google Scholar
• Rosen CF, Mussani F, Chandran V, et al. Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. Rheumatology (Oxford) 2012;51:571-6
   PubMed Web of Science ®Google Scholar
• Dean LE, Jones GT, MacDonald AG, et al. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford) 2014;53:650-7
   PubMed Web of Science ®Google Scholar
• Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008;58:15-25
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SP, Deodhar A. The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun 2014;48–49:128-33
   PubMed Web of Science ®Google Scholar
• ORENCIA® (abatacept) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Company, 2015
   Google Scholar
• Humira® (adalimumab) Prescribing Information. North Chicago, IL: AbbVie Inc., 2014
   Google Scholar
• CIMZIA® (certolizumab pegol) Prescribing Information. Smyrna, GA: UCB, Inc., 2013
   Google Scholar
• Enbrel® (etanercept) Prescribing Information. Thousand Oaks, CA: lmmunex Corporation, 2015
   Google Scholar
• SIMPONI® (golimumab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc., 2014
   Google Scholar
• Remicade® (infliximab) Prescribing Information. Malvern, PA: Janssen Biotech, Inc., 2015
   Google Scholar
• RITUXAN® (rituximab) Prescribing Information. South San Francisco, CA: Genentech, Inc., 2014
   Google Scholar
• ACTEMRA® (tocilizumab) Prescribing Information. South San Francisco, CA: Genentech, Inc., 2014
   Google Scholar
• STELARA® (ustekinumab) Prescribing Information. Horsham, PA: Janssen Biotech, Inc., 2014
   Google Scholar
• Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Med 2013;11:88
   PubMed Web of Science ®Google Scholar
• Bonafede MM, Gandra SR, Watson C, et al. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther 2012;29:234-48
   PubMed Web of Science ®Google Scholar
• Bonafede M, Joseph GJ, Princic N, et al. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis. J Med Econ 2013;16:1120-8
   PubMedGoogle Scholar
• Howe A, Eyck LT, Dufour R, et al. Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database. J Manag Care Spec Pharm 2014;20:1236-44
   PubMed Web of Science ®Google Scholar
• Joyce AT, Gandra SR, Fox KM, et al. National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naive rheumatoid arthritis patients in US health plans. J Med Econ 2014;17:1-10
   PubMedGoogle Scholar
• Schabert VF, Watson C, Gandra SR, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2012;15:264-75
   PubMedGoogle Scholar
• Schabert VF, Watson C, Joseph GJ, et al. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population. J Manag Care Pharm 2013;19:621-30
   PubMed Web of Science ®Google Scholar
• Wu N, Lee YC, Shah N, et al. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study. Clin Ther 2014;36:1231-41, 41 e1–3
   PubMed Web of Science ®Google Scholar
• Bonafede M, Joseph GJ, Shah N, et al. Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population. Clinicoecon Outcomes Res 2014;6:381-8
   PubMedGoogle Scholar
• Fihn SD, Francis J, Clancy C, et al. Insights from advanced analytics at the Veterans Health Administration. Health Aff (Millwood) 2014;33:1203-11
   PubMed Web of Science ®Google Scholar
• Nelson SD, Lu CC, Teng CC, et al. The use of natural language processing of infusion notes to identify outpatient infusions. Pharmacoepidemiol Drug Saf 2015;24:86-92
   PubMed Web of Science ®Google Scholar
• Lu CC, Leng J, Cannon G, et al. Accuracy of a natural language processing software designed to compute average weekly dose from narrative medication schedule [abstract]. Value Health 2014;17:A187-8
   Web of Science ®Google Scholar
• Cannon GW, Mikuls TR, Hayden CL, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011;63:1680-90
   PubMed Web of Science ®Google Scholar
• Cannon GW, DuVall SL, Haroldsen CL, et al. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis. J Rheumatol 2014;41:1935-43
   PubMed Web of Science ®Google Scholar
• Bonafede M, Fox KM, Watson C, et al. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012;29:664-74
   PubMed Web of Science ®Google Scholar